Literature DB >> 2506958

Factor VIII structure and function.

P A Foster1, T S Zimmerman.   

Abstract

The relatively recent ability to obtain highly purified factor VIII (FVIII) preparations from plasma products, the cloning of the FVIII gene, and the expression of recombinant FVIII have provided the basis for significant advancements in the understanding of the structure-function relationships of FVIII. Evaluation of the molecular structure of FVIII has revealed the presence of domains of significant internal amino acid sequence homology as well as homology with similar structural domains of factor V. Specific proteolytic cleavage sites have been identified in the molecule and the use of site directed mutagenesis has identified those proteolytic cleavage sites required for the activation of FVIII. Deletion and substitution variants of FVIII as well as the precise epitope mapping of FVIII antibodies which inhibit the procoagulant function of the protein or its binding to von Willebrand factor have provided insight into the identification of regions of FVIII which are required for normal function.

Entities:  

Mesh:

Substances:

Year:  1989        PMID: 2506958     DOI: 10.1016/0268-960x(89)90015-5

Source DB:  PubMed          Journal:  Blood Rev        ISSN: 0268-960X            Impact factor:   8.250


  19 in total

1.  Downregulation of CD40 signal and induction of TGF-β by phosphatidylinositol mediates reduction in immunogenicity against recombinant human Factor VIII.

Authors:  Puneet Gaitonde; Aaron Peng; Robert M Straubinger; Richard B Bankert; Sathy V Balu-Iyer
Journal:  J Pharm Sci       Date:  2011-09-23       Impact factor: 3.534

2.  Influence of aggregation on immunogenicity of recombinant human Factor VIII in hemophilia A mice.

Authors:  Vivek S Purohit; C Russell Middaugh; Sathyamangalam V Balasubramanian
Journal:  J Pharm Sci       Date:  2006-02       Impact factor: 3.534

3.  Interaction of dicaproyl phosphatidylserine with recombinant factor VIII and its impact on immunogenicity.

Authors:  Vivek S Purohit; Sathyamangalam V Balasubramanian
Journal:  AAPS J       Date:  2006-05-26       Impact factor: 4.009

4.  Healthy subjects produce both anti-factor VIII and specific anti-idiotypic antibodies.

Authors:  J G Gilles; J M Saint-Remy
Journal:  J Clin Invest       Date:  1994-10       Impact factor: 14.808

5.  Evaluation of genetic stability of recombinant human factor VIII by peptide mapping and on-line mass spectrometric analysis.

Authors:  M J Besman; D Shiba
Journal:  Pharm Res       Date:  1997-08       Impact factor: 4.200

6.  Intravenous administration of Factor VIII-O-Phospho-L-Serine (OPLS) complex reduces immunogenicity and preserves pharmacokinetics of the therapeutic protein.

Authors:  Puneet Gaitonde; Vivek S Purohit; Sathy V Balu-Iyer
Journal:  Eur J Pharm Sci       Date:  2014-10-20       Impact factor: 4.384

7.  Antibodies to factor VIII in plasma of patients with hemophilia A and normal subjects.

Authors:  J Batlle; E Gómez; E Rendal; J Torea; E Lourés; M Couselo; P Vila; C Sedano; X Tusell; M Magallón; M Quintana; R González-Boullosa; M F López-Fernández
Journal:  Ann Hematol       Date:  1996-05       Impact factor: 3.673

Review 8.  Blood coagulation factor VIII: An overview.

Authors:  G M Bhopale; R K Nanda
Journal:  J Biosci       Date:  2003-12       Impact factor: 1.826

9.  Haemophilia A: database of nucleotide substitutions, deletions, insertions and rearrangements of the factor VIII gene.

Authors:  E G Tuddenham; D N Cooper; J Gitschier; M Higuchi; L W Hoyer; A Yoshioka; I R Peake; R Schwaab; K Olek; H H Kazazian
Journal:  Nucleic Acids Res       Date:  1991-09-25       Impact factor: 16.971

10.  Evidence that a secondary binding and protecting site for factor VIII on von Willebrand factor is highly unlikely.

Authors:  S Layet; J P Girma; B Obert; E Peynaud-Debayle; N Bihoreau; D Meyer
Journal:  Biochem J       Date:  1992-02-15       Impact factor: 3.857

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.